Nasser Ghaly Yousif

Secondary EGFR Mutations and MET Amplification Underlying Osimertinib Resistance in Advanced Non–Small Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Pooled Analysis

Background Osimertinib is the preferred first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for advanced EGFR-mutated non–small cell lung cancer (NSCLC), but acquired resistance remains inevitable and is characterized by substantial molecular heterogeneity. Secondary EGFR mutations and MET ampl...